S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST

Autor: Richard Schlenk, Pau Montesinos, Antonio Romero-Aguilar, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, James Hanyok, LI Liu, Yasser Mostafa Kamel, Aziz Benzohra, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Alexander E. Perl, Mark J. Levis, Harry P. Erba

Publikováno v: HemaSphere, Vol 7, p e61150fb (2023)

Externí odkaz: https://doaj.org/article/161ac30cf9634f0ab1e0c386b591f284

P538: FAST-TRACK MEASURABLE RESIDUAL DISEASE DETECTION BY MULTIPARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Autor: Maximilian Roehnert, Michael Kramer, Jonas Schadt, Philipp Ensel, Christoph Roellig, Johannes Schetelig, Friedrich Stoelzel, Richard Schlenk, Martin Bornhaueser, Malte von Bonin, Uta Oelschlaegel

Publikováno v: HemaSphere, Vol 7, p e175805c (2023)

Externí odkaz: https://doaj.org/article/1e675d38912848e18909005f52c3b21d

P1024: MYLOX-1: A PHASE II STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL LOXL2 INHIBITOR GB2064 (WITH FOCUS ON BONE MARROW COLLAGEN) IN PATIENTS WITH MYELOFIBROSIS

Autor: Claire Harrison, John Mascarenhas, Daniela Cilloni, Richard Schlenk, Brian Jacoby, Robert J Slack, Vassilios Aslanis, Bhupinder Singh, Bertil Lindmark, Srdan Verstovsek, Raajit K Rampal

Publikováno v: HemaSphere, Vol 7, p e87048d4 (2023)

Externí odkaz: https://doaj.org/article/62f833fe9a3d493fa9bb83c9fd449bd4

Community-driven development of a modified progression-free survival ratio for precision oncology

Autor: Sebastian Schölch, Benedikt Brors, Albrecht Stenzinger, Ursula Ehmer, Ulrich-Frank Pape, Christoph Springfeld, Dirk Jäger, Felix J Hüttner, Andreas Mock, Christoph E Heilig, Simon Kreutzfeldt, Daniel Huebschmann, Christoph Heining, Evelin Schröck, Richard Schlenk, Hanno Glimm, Stefan Fröhling, Peter Horak, Leonidas Apostolidis, Marinela Augustin, Daniela Aust, Irfan Ahmed Bhatti, Johannes Bloehdorn, Cornelia Brendel, Christian Britschgi, Jan Braess, Stefan Burdach, Elena Busch, Jozefina Casuscelli, Alexander Desuki, Thomas Deutsch, Mareike Dietrich, Thomas J Ettrich, Johanna Falkenhorst, Tanja Fehm, Anne Flörcken, Andrea Forschner, Stefan Fuxius, Maria Gonzales-Carmona, Frank Griesinger, Sabine Grill, Stefan Gröschel, Georg Martin Haag, Ulrich Haag, Niels Halama, Holger Hebart, Nina Heidger, Barbara Hermes, Georg Hess, Simone Hettmer, Manuela Hoechstetter, Martin Hoffmann, Anna L Illert, Maximilian Jenzer, Bernd Kasper, Stefan Kasper-Virchow, Thomas Kindler, Ewa Koscielniak, Jan Krönke, Michael Kühn, Volker Kunzmann, Alois Lang, Jonas Leichsenring, Elisabeth Livingstone, Lucia Liotta, Kim Luley, Elisabeth Mack, Uwe M Martens, Klaus Metzeler, Jan Moritz Middeke, Lino Möhrmann, Roopa Jayarama-Naidu, Lukas Perkhofer, Arne Pfeufer, Constantin Pixberg, Michael Quante, Bernhard Rendenbach, Damian Rieke, Christian Rothermundt, Andre Norbert Sagerer, Martin Salzmann, Dieter Saur, Bastian Schilling, Jan Schleicher, Anke Schlenska-Lange, Thomas Schmidt, Sophia Schmitz, Rajiv Shah, Khalid Shoumariyeh, Alexander Siebenhüner, Martin Singh, Jens Siveke, Helen Starke, Sophia Strobel, Veronica Teleanu, Niklas Thon, Sebastian Wagner, Thomas Walle, Benedikt Westphalen, Bettina Whitlock, Eva Winkler, Naita Maren Wirsik, Lena Woydack, Angelika Zabel-du Bois, Stefanie Zschäbitz

Publikováno v: ESMO Open, Vol 4, Iss 6 (2019)

Objective Measuring the success of molecularly guided therapies is a major challenge in precision oncology trials. A commonly used endpoint is an intra-patient progression-free survival (PFS) ratio, defined as the PFS interval associated with molecul

Externí odkaz: https://doaj.org/article/0122f1ac148444cbaeb951db5af876a5

Therapy-related myeloid neoplasms following treatment with radioiodine

Autor: Thomas Schroeder, Andrea Kuendgen, Sabine Kayser, Nicolaus Kröger, Friederike Braulke, Uwe Platzbecker, Viola Klärner, Fabian Zohren, Detlef Haase, Michael Stadler, Richard Schlenk, Akos G. Czibere, Ingmar Bruns, Roland Fenk, Norbert Gattermann, Rainer Haas, Guido Kobbe, Ulrich Germing

Publikováno v: Haematologica, Vol 97, Iss 2 (2012)

Background Few data are available on therapy-related myelodysplastic syndromes and acute myeloid leukemia developing after radioiodine treatment.Design and Methods We retrospectively analyzed 39 patients with myeloid neoplasms following radioiodine t

Externí odkaz: https://doaj.org/article/f90649af53cf4272acbb9e1f7703d17d